Shares in Clovis Oncology dipped as much as 14% Friday, which some analysts suspect was due to investor disappointment in the number of parties that offered to acquire one of its main rivals, Tesaro.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,